Pharmacophore-based virtual screening from phytocannabinoids as antagonist r-CB1.

Area of Science:

• Pharmacology and Medicinal Chemistry
• Computational Drug Discovery

Background:

• Obesity management seeks safe, long-term pharmacological treatments.
• The endocannabinoid system plays a role in appetite regulation and obesity.
• Cannabis sativa contains phytocannabinoids with therapeutic potential.

Purpose of the Study:

• To identify novel anti-obesity phytocannabinoids from Cannabis sativa.
• To evaluate their potential interaction with the cannabinoid receptor 1 (CB1).
• To assess safety and efficacy through in silico methods.

Main Methods:

• Pharmacophore-based virtual screening of C. sativa phytocannabinoids.
• Inclusion of physicochemical, pharmacokinetic, and toxicological predictions.
• Molecular docking and molecular dynamics (MD) studies.

Main Results:

• Two molecules, Zinc 69 (ZINC33053402) and Zinc 70 (ZINC19084698), were identified as potential anti-obesity agents.
• MD studies confirmed complex stability (RMSD analysis).
• Binding free energy calculations indicated inhibitory potential against the target.

Conclusions:

• Identified phytocannabinoids show promise as safe and effective anti-obesity agents.
• These compounds may offer a safer alternative to synthetic cannabinoids.
• Further research into these molecules could lead to new obesity treatments.